Trials / Conditions / Myeloproliferative Neoplasms

Myeloproliferative Neoplasms

23 registered clinical trials studyying Myeloproliferative Neoplasms — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Study of INCA036978 in Participants With Myeloproliferative Neoplasms NCT07441694	Incyte Corporation	Phase 1
Recruiting	A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms NCT07008118	Incyte Corporation	Phase 1
Recruiting	MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People NCT07362225	MPN Research Foundation	—
Recruiting	Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gen NCT06291987	University of Chicago	Phase 1
Recruiting	A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms NCT06313593	Incyte Corporation	Phase 1
Recruiting	A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participant NCT06034002	Incyte Corporation	Phase 1
Recruiting	A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participant NCT05936359	Incyte Corporation	Phase 1
Completed	A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment NCT05444530	Janssen Research & Development, LLC	Phase 1
Terminated	Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. NCT04866056	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	Phase 1 / Phase 2
Active Not Recruiting	Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders NCT04761770	Memorial Sloan Kettering Cancer Center	Phase 2
Active Not Recruiting	A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT NCT03912064	Dana-Farber Cancer Institute	Phase 1
Unknown	A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms NCT04339400	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 1
Recruiting	Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders NCT03314974	Masonic Cancer Center, University of Minnesota	Phase 2
Active Not Recruiting	Registry of Patients With MPNs in Taiwan NCT03618485	Chang Gung Memorial Hospital	—
Unknown	Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Disorders NCT02823210	Assistance Publique - Hôpitaux de Paris	—
Completed	A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms NCT03075826	Weill Medical College of Cornell University	Phase 2
Terminated	Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) NCT02393248	Incyte Corporation	Phase 1 / Phase 2
Completed	A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow D NCT02125318	Galena Biopharma, Inc.	Phase 2
Completed	Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML NCT02076191	John Mascarenhas	Phase 1 / Phase 2
Completed	Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms NCT02084563	Hospital Israelita Albert Einstein	Phase 2
Terminated	HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (P NCT01668173	Memorial Sloan Kettering Cancer Center	Phase 2
Completed	Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage NCT00949364	University of Ulm	Phase 2
Completed	Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer NCT00053196	Alliance for Clinical Trials in Oncology	Phase 2